Nyanza Reproductive Health Society, Kisumu, Kenya.
Department of Microbiology & Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Int J STD AIDS. 2024 Oct;35(12):935-943. doi: 10.1177/09564624241273774. Epub 2024 Aug 14.
We characterized the antimicrobial resistance (AMR) profiles of (NG) isolated from symptomatic men at a sexually transmitted infection clinic in Kisumu, Kenya.
Two urethral swabs were obtained from symptomatic men between 2020 and 2022, one for Gram's stain and the other inoculated directly onto modified Thayer-Martin media containing 1% VCNT and 1% IsoVitaleX enrichment. Culture results were confirmed by colony morphology, Gram's stain and oxidase test. Duplicate isolates were shipped to Uniformed Services University for confirmation and characterization. Susceptibility to eight drugs was assessed by E-test. Agar dilution confirmed resistance to ceftriaxone, cefixime, and azithromycin. Susceptibility, intermediate resistance (IR), and resistance (R) were determined according to published criteria.
Of 154 enrolled participants, 112 were culture-positive for NG. Agar dilution results in 110 (98.2%) showed the following: azithromycin-R (1.8%), and 4.5% R or IR to ceftriaxone or cefixime: ceftriaxone-R (0.9%), ceftriaxone-IR (2.7%), and cefixime-IR (2.7%). By E-test, most isolates were IR or R to tetracycline (97.2%), penicillin (90.9%), and ciprofloxacin (95.4%).
We detected NG with resistance to azithromycin and ceftriaxone, indicating a growing threat to the current Kenyan dual syndromic treatment of urethritis with cephalosporin plus macrolides. Ongoing AMR surveillance is essential for effective drug choices.
我们对肯尼亚基苏木性传播感染诊所的症状男性中分离出的淋病奈瑟菌(NG)的抗菌药物耐药(AMR)谱进行了特征描述。
在 2020 年至 2022 年期间,从症状男性中采集了两个尿道拭子,一个用于革兰氏染色,另一个直接接种到含有 1% VCNT 和 1% IsoVitaleX 富集的改良 Thayer-Martin 培养基中。通过菌落形态、革兰氏染色和氧化酶试验确认培养结果。将重复分离株运往统一服务大学进行确认和特征描述。通过 E 试验评估对八种药物的敏感性。琼脂稀释法证实对头孢曲松、头孢克肟和阿奇霉素耐药。根据已发表的标准确定敏感性、中介耐药(IR)和耐药(R)。
在 154 名入组参与者中,有 112 名 NG 培养阳性。110 份琼脂稀释结果(98.2%)显示以下结果:阿奇霉素 R(1.8%),头孢曲松或头孢克肟 R 或 IR(4.5%):头孢曲松 R(0.9%),头孢曲松 IR(2.7%)和头孢克肟 IR(2.7%)。通过 E 试验,大多数分离株对四环素(97.2%)、青霉素(90.9%)和环丙沙星(95.4%)表现出 IR 或 R。
我们检测到对阿奇霉素和头孢曲松耐药的 NG,表明当前肯尼亚用头孢菌素加大环内酯类药物联合治疗尿道炎的双重综合征治疗方法面临日益严重的威胁。持续的 AMR 监测对于有效选择药物至关重要。